Abstract 1436P
Background
To understand if there is sex disparity in survival outcomes among the patients with advanced gastric adenocarcinoma (GAC), gastroesophageal junction adenocarcinoma (GEJAC), and esophageal adenocarcinoma (EAC).
Methods
The study included patients from Kaiser Permanente Northern California with metastatic or relapsed EAC, GEJAC and GAC whose tumor underwent next-generation sequencing. We used Cox regression modeling to examine association of male and female patients with overall survival (OS) adjusting for demographics, performance status, Charlson comorbidity index, receipt of chemotherapy, and six most common genomic alterations including HER2 overexpression/amplification, p53, KRAS, CDKN2A, PIK3CA co-mutation and Myc amplification.
Results
Among 875 eligible patients, 275 were female and 600 were male. OS for male versus female patients did not appear substantially different for the entire cohort (HR = 0.87; [95% CI, 0.74-1.03]), for EAC (HR = 1.0; [95% CI, 0.57-1.74]) and GEJAC (HR = 1.14; (95% CI, 0.77-1.67]) subgroups. However, OS of male versus female patients with GAC appeared substantially better (HR = 0.75; [95% CI, 0.60-0.93]). In addition, this substantial OS difference was preserved regardless of HER2 status, CDKN2A and PIK3CA mutation or Myc amplification. Intriguingly, despite overall there was no OS difference between male versus female GAC patients regardless of p53 mutation status, however, among GAC patients with a p53 mutation, male had substantially better OS than female patients only if tumor carried non-gain-of-function (non-GOF, HR = 0.59; [95% CI, 0.41-0.85]) but not gain-of-function mutation (GOF, HR = 1.46; [95% CI, 0.74-2.87]).
Conclusions
We have found that male versus female GAC patients had substantially better overall survival. Most intriguingly, the survival difference among patients with mutp53 was only observed if tumor carried mutp53 non-GOF. Our results for the first time identified a sex disparity in survival outcomes that is associated with a common molecular lesion and can have important implications in understanding the biology of GAC and in clinical practice for prognostic stratification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1468P - cGAS-driven inflammation in chromosomally unstable oesophagogastric adenocarcinoma
Presenter: Eileen Parkes
Session: Poster session 18
1469P - Development of an efficacy prediction model for concurrent chemoradiotherapy in esophageal squamous cell carcinoma using deep learning and multimodal data integration
Presenter: Xin Yang
Session: Poster session 18
1470TiP - Phase I trial of intraperitoneal infusion of GAIA-102 of NK-Like CD3-negative cells for gastric/pancreatic cancer
Presenter: Eiji Oki
Session: Poster session 18
1471TiP - MK-2870-015: A phase III study of trophoblast antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) vs treatment of physician’s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA)
Presenter: Zev Wainberg
Session: Poster session 18
1472TiP - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group – The IKF-057/ PRESTO trial
Presenter: Nils Homann
Session: Poster session 18
1473TiP - Neoadjuvant SOX combined with cadonilimab (AK104) for PD-L1 negative upper GC/GEJC patients
Presenter: Zhen Yuan
Session: Poster session 18
1474TiP - A randomized phase II study of disitamab vedotin (DV) plus toripalimab and chemotherapy versus DV plus toripalimab versus chemotherapy as perioperative treatment for HER2-expressing locally advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ)
Presenter: Ziyu Li
Session: Poster session 18
1475TiP - Fruquintinib in combination with sintilimab and CAPEOX as first-line treatment for advanced G/GEJ cancer: A phase Ib/II clinical trial (FUNCTION)
Presenter: Bei-Bei Chen
Session: Poster session 18